Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMT-TRIAAL ascorbic acid trial in Charcot-Marie-Tooth disease type 1A
2006-000032-27Phase 3Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Charcot-Marie-Tooth disease type 1A (CMT1A) comparing Ascorbic acid with Placebo (2 arms). Primary endpoint: Effect of ascorbic acid on CMT Neuropathy Score. Started Mar 2006; status: completed.
02
Drugs
ascorbic acid
03
Conditions
Charcot-Marie-Tooth disease type 1A (CMT1A)
Beyond the preview
Go deeper on 2006-000032-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000032-27.